Tumor Suppression
Return to Library
|
Free Tumor Suppression Articles |
- New findings from Veterans Affairs Medical Center describe advances in gene therapy
- New research on lung cancer risk factors from Taipei Veterans General Hospital, Department of Surgery summarized
- Rare cancer-causing syndrome found, for the first time, in Singapore
- Report summarizes cancer gene therapy study findings from University of Texas, M.D. Anderson Cancer Center
- Reports from McGill University, Department of Biochemistry describe recent advances in spermatogenesis
- Reports from University Leipzig advance knowledge in gene therapy
- Research conducted at University of Pennsylvania, Abramson Family Cancer Research Institute has provided new information about Kaposi sarcoma cell biology
- Research conducted at University of Texas, M.D. Anderson Cancer Center has updated our knowledge about B-cell lymphoma genetics
- Research from College of Medicine in the area of DNA research published
- Research from Washington University broadens understanding of gene therapy
- Research reports from Genomics Research Center provide new insights into gene therapy
- Research reports from University of Chile, Center for Molecular Studies provide new insights into apoptosis cell biology
- Scientists at Peking Union Medical College discuss research in cardia cancer risk factors
- Scientists at Shiga University publish research in Alzheimer disease
- Studies from M. Hager and co-researchers yield new data on gene therapy
- Studies from Ohio State University, Comprehensive Cancer Center describe new findings in hepatocellular cancer therapy
- Studies from Peking University, Center for Human Disease Genomics reveal new findings on gene therapy
- Studies from University Hospital have provided new information about colon cancer genetics
- Studies from University of Athens provide new data on non-small cell lung cancer
|
|
|
New data from Harvard University, Dana-Farber Cancer Institute illuminate research in gene therapy
2007 NOV 19 -- Scientists discuss in 'pVHL Acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2' new findings in gene therapy. "The VHL tumor suppressor protein (pVHL) is part of an E3 ubiquitin ligase that targets HIF for destruction. pVHL-defective renal carcinoma cells exhibit increased NF-kappaB activity but the mechanism is unclear. NF-kappaB affects tumorigenesis and therapeutic resistance in some settings," researchers in the United States report. "We found that pVHL associates with the NF-kappaB agonist Card9 but does not target Card9 for destruction. Instead, pVHL serves as an adaptor that promotes the phosphorylation of the Card9 C terminus by CK2. Elimination of these sites markedly enhanced Card9's ability to activate NF-kappaB in VHL(+/+) cells, and Card9 siRNA normalized NF-kappaB activity in VHL(-/-) cells and restored their sensitivity to cytokine-induced apoptosis. Furthermore, downregulation of Card9 in VHL(-/-) cancer cells reduced their tumorigenic potential. Therefore pVHL can serve as an adaptor for both a ubiquitin conjugating enzyme and a kinase," wrote H. Yang and colleagues, Harvard University, Dana-Farber Cancer Institute. The researchers concluded: "The latter activity, which promotes Card9 phosphorylation, links pVHL to control of NF-kappaB activity and tumorigenesis." Yang and colleagues published their study in Molecular Cell (pVHL Acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Molecular Cell, 2007;28(1):15-27). For additional information, contact H. Yang, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dept. of Medical Oncology, Harvard Medical School, Boston, MA 02115 USA.. Publisher contact information for the journal Molecular Cell is: Cell Press, 1100 Massachusetts Avenue, Cambridge, MA 02138, USA. Keywords: United States, Boston, Biotechnology, Gene Therapy, Oncology, Treatment, Tumor Suppression. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
